WeDaita

Research Digest

AI-curated papers, approvals, clinical compounds, and disclosures from drug discovery's leading sources.

Scored for relevance by WeDaita AI · Updated weekly · Not editorial content

Computational and medicinal chemistry advances, approved drugs, and clinical pipeline entries across the full drug design lifecycle.

  • Literature — AI-driven molecular generation, virtual screening, ADMET prediction, and structure-based design from PubMed, arXiv, and Semantic Scholar
  • FDA Approval — Recently approved small-molecule drugs (NDA approvals) sourced from openFDA
  • Clinical Compound — Phase I–III candidates from ChEMBL — molecules in active clinical development not yet approved
  • Disclosure — New molecular series and compound profiles curated by Drug Hunter
  • Patent — Drug Hunter Patent Gazette roundups with expert annotations on assignees, targets, and key novelty claims
  • Industry News — Company announcements, funding rounds, and biotech media coverage
Industry News
Earlier Toxicity Insight Through Proteomic Profiling
Sep 11, 2026 · FierceBiotech · dfarris
Industry News
Selective oestrogen receptor degrader class grows with new cancer approval
Sep 11, 2026 · Nature Reviews Drug Discovery · Asher Mullard
Industry News
Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
Sep 11, 2026 · Drug Hunter